A pharmaceutical company conducts a randomized, double-blind non-inferiority trial compari… — USMLE Step 2 CK

A pharmaceutical company conducts a randomized, double-blind non-inferiority trial comparing a novel once-daily oral antibiotic to the standard thrice-daily intravenous therapy for the treatment of uncomplicated pyelonephritis. The primary endpoint is the clinical cure rate at $14$ days. The investigators establish a predefined non-inferiority margin ( $\Delta$ ) of $-6.0\%$ , meaning the new oral antibiotic will be deemed non-inferior if its cure rate is no more than $6.0$ absolute percentage points lower than the standard therapy.

Upon study completion, the absolute difference in clinical cure rates (novel antibiotic minus standard therapy) is calculated to be $-3.0\%$ . The $95\%$ confidence interval (CI) for this difference is $[-5.2\%, -0.8\%]$ , with a one-sided $p$ -value of $0.01$ for non-inferiority.

Based on the information above, which of the following is the most accurate statistical interpretation of these trial results?

The novel antibiotic is non-inferior to the standard therapy, but it is statistically less effective.Answer
B
The novel antibiotic failed to demonstrate non-inferiority because the confidence interval does not cross $0\%$ .
C
The novel antibiotic is considered superior to the standard therapy because the associated $p$ -value is less than $0.05$ .
D
The trial results are invalid due to unmeasured confounding, as the treatment effect estimate remains entirely negative.
E
The positive predictive value of achieving a clinical cure with the novel antibiotic is inherently reduced by the $-6.0\%$ margin.

Answer

The novel antibiotic is non-inferior to the standard therapy, but it is statistically less effective.

In a non-inferiority trial, a new treatment is considered non-inferior if the lower bound of the

95\%

confidence interval for the treatment difference sits above the predefined negative non-inferiority margin (

-\Delta

). Here, the lower bound is

-5.2\%

, which is greater than the

-6.0\%

margin, confirming non-inferiority. However, because the entire confidence interval

[-5.2\%, -0.8\%]

falls below

0\%

, the novel antibiotic is statistically significantly less effective than the standard therapy. This often occurs when a drug trades a small, acceptable loss in efficacy for other clinical benefits, such as a more convenient dosing route.

Step-by-Step Solution

Evaluate the confidence interval against the non-inferiority margin.

The lower bound of the

95\%

CI is

-5.2\%

. This is greater (closer to zero) than the non-inferiority margin of

-6.0\%

To prove non-inferiority, the worst-case scenario (lower bound of the CI) must not cross the predefined unacceptable difference (

\Delta

Evaluate the confidence interval against the line of no difference (null hypothesis for superiority).

The upper bound of the

95\%

CI is

-0.8\%

, which is strictly less than

0\%

If a confidence interval for an absolute difference does not cross

0\%

, the difference is statistically significant. Since it is entirely negative, the novel drug is statistically less effective.

Synthesize the findings to form a complete clinical and statistical conclusion.

The novel antibiotic meets the criteria for non-inferiority but is simultaneously statistically inferior in efficacy compared to the standard therapy.

This is a common and valid outcome in non-inferiority trials, often accepted because the new drug provides auxiliary benefits (e.g., oral administration vs. intravenous).

Key Concept

Confidence interval interpretation in non-inferiority trials

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic